ClinicalTrials.gg

Program

OMS1620

A development code.

Its studies are mostly in Adrenal Hyperplasia, Congenital, led by OMass Therapeutics Australia Proprietary.

Furthest: phase 1, since Aug 10, 20261 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
OMass Therapeutics Australia Proprietary11 open or runningphase 1since Aug 10, 2026Aug 10, 2026May 2027phase 1 · NCT07811089

Also a collaborator on its studies: omass-therapeutics.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 10, 2026First study: phase 1 study in Adrenal Hyperplasia, CongenitalFirst studyNCT07811089 · 84 planned

Ahead

  1. May 2027Primary completion: phase 1 study in Adrenal Hyperplasia, CongenitalNCT07811089

TargetBeta

MC2R →POMC →read by rule
“OMS1620 is an oral small molecule antagonist of the melanocortin 2 receptor (MC2R), the receptor for adrenocorticotrophic hormone (ACTH)”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
atumelnantruleVertex Pharmaceuticalsphase 38

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811089Adrenal Hyperplasia, Congenital1Not yet recruitingMay 202784

How it is read

Names in the registry

  • “OMS1620”, 1 entry

Codes read as this program: OMS1620.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.